What is the translation of " DOES NOT INHIBIT " in Croatian?

• ne inhibira

Examples of using Does not inhibit in English and their translations into Croatian

How much is depnie wheels to lock and the car glides on rails how to gently press- does not inhibit.
Koliko je depnie kotači za zaključavanje i auto klizi na tračnice kako nježno za tisak- ne inhibiraju.

Rivaroxaban does not inhibit thrombin(activated Factor II) and no effects on platelets have been demonstrated.
Rivaroksaban ne inhibira trombin(aktivirani faktor II), a nisu pokazani ni učinci na trombocite.

Based on in vitro studies, empagliflozin does not inhibit, inactivate, or induce CYP450 isoforms.
Na temelju in vitro ispitivanja empagliflozin ne inhibira, ne inaktivira niti ne inducira izoforme CYP450.

Dasabuvir does not inhibit organic anion transporter(OAT1) in vivo as shown by the lack of interaction with tenofovir OAT1 substrate.
Dasabuvir ne inhibira prijenosnik organskih aniona(OAT1) in vivo što je pokazao izostanak interakcije s tenofovirom supstrat za OAT1.

Sitagliptin is a potent and highly selective inhibitor of the enzyme DPP-4 and does not inhibit the closely-related enzymes DPP-8 or DPP-9 at therapeutic concentrations.
Sitagliptin je potentan i visoko selektivan inhibitor enzima DPP-4 te pri terapijskim koncentracijama ne inhibira njemu vrlo srodne enzime DPP-8 ili DPP-9.

Desloratadine does not inhibit CYP3A4 in vivo, and in vitro studies have shown that the medicinal product does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein.
Desloratadin ne inhibira CYP3A4 in vivo, a in vitro studije su pokazale da lijek ne inhibira CYP2D6 i da nije supstrat niti inhibitor P-glikoproteina.

Based on in vitro data, pomalidomide is not an inhibitor or inducer of cytochrome P-450 isoenzymes, and does not inhibit any drug transporters that were studied.
Na temelju podataka in vitro, pomalidomid nije ni inhibitor niti induktor izoenzima citokroma P-450 i ne inhibira nijedan od prijenosnika koji su bili ispitani.

When used in a small dosage, the substance does not inhibit the respiratory center, it does not adversely affect the activity of the ciliated epithelium.
Kada se koristi u malim dozama, tvar ne inhibira dišni centar, ne utječe negativno na aktivnost ciliiranog epitela.

Regadenoson does not inhibit the metabolism of substrates for CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 in human liver microsomes, indicating that it is unlikely to alter the pharmacokinetics of medicinal products metabolised by these cytochrome P450 enzymes.
Regadenoson ne inhibira metabolizam supstrata za CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, ili CYP3A4 u mikrosomima ljudske jetre, što ukazuje da nije vjerojatno da će djelovati na farmakokinetiku lijekova koji se metaboliziraju pomoću enzima citokrom P450.

In vitro studies using Caco-2 cells indicate that tigecycline does not inhibit digoxin flux, suggesting that tigecycline is not a P-glycoprotein(P-gp) inhibitor.
In vitro ispitivanja koristeći Caco-2 stanice ukazuju da tigeciklin ne inhibira protok digoksina, sugerirajući da tigeciklin nije P-glikoproteinski(P-gp) inhibitor.

Ambrisentan does not inhibit or induce phase I or II drug metabolising enzymes at clinically relevant concentrations in in vitro and in vivo non-clinical studies, suggesting a low potential for ambrisentan to alter the profile of medicinal products metabolised by these pathways.
Ambrisentan ne inhibira niti inducira enzime faze I ili II metabolizma lijekova u klinički značajnim koncentracijama u in vitro i in vivo nekliničkim ispitivanjima, što sugerira malu sposobnost ambrisentana u mijenjanju svojstva lijekova koji se metaboliziraju na ovaj način.

In-vitro studies in human liver microsomes indicate that ertapenem does not inhibit metabolism mediated by any of the six major CYP isoforms: 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4.
In vitro studije na humanim jetrenim mikrosomima pokazuju da ertapenem ne inhibira metabolizam posredovan bilo kojim od šest glavnih CYP izoformi: 1A2, 2C9, 2C19, 2D6, 2E1 i 3A4.

Carfilzomib does not inhibit human UGT2B7 but inhibits human UGT1A1 with an IC50 of 5.5 µM. Nonetheless, considering the fast elimination of carfilzomib, notably a rapid decline in systemic concentration 5 minutes after the end of infusion, the risk of clinically relevant interactions with substrates of OATP1B1 and UGT1A1 is probably low.
Karfilzomib ne inhibira humani UGT2B7, ali inhibira humani UGT1A1 uz IC50 vrijednosti od 5, 5 µM. Ipak, uzimajući u obzir brzu eliminaciju karfilzomiba, posebno brz pad sistemske koncentracije 5 minuta nakon završetka infuzije, rizik od klinički relevantnih interakcija sa supstratima OATP1B1 i UGT1A1 vjerojatno je nizak.

No-clean flux residue is acceptable on all 3 classes of PCBs as defined by IPC-610 provided it does not inhibit visual inspection, access to test points, or have a wet, tacky or excessive residue that may spread onto other areas.
Ne čistite toka talog je prihvatljivo na sve 3 klase PCB definiran IPC 610 pod uvjetom da to ne inhibiraju vizualni pregled, pristup test bodove, ili su mokra, ljepljiva ili prekomjerno ostatak koji se može proširiti na druga područja.

Based on in vitro data, ceritinib does not inhibit apical efflux transporter MRP2, hepatic uptake transporters OATP1B1 or OATP1B3, renal organic anion uptake transporters OAT1 and OAT3, or the organic cation uptake transporters OCT1 or OCT2 at clinically relevant concentrations.
Na temelju in vitro podataka, ceritinib ne inhibira apikalni efluksni transporter MRP2, transportere unosa u jetru OATP1B1 ili OATP1B3, bubrežne transportere za unos organskih aniona OAT1 i OAT3, ili transportere za unos organskih kationa OCT1 ili OCT2 pri klinički relevantnim koncentracijama.

Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans(< 2% of a dose recovered in urine as metabolites), does not inhibit drug metabolism in vitro, and is not bound to plasma proteins, it is unlikely to produce, or be subject to, pharmacokinetic interactions.
Budući da se pregabalin pretežno izlučuje mokraćom u nepromijenjenom obliku, da je u čovjeka podložan zanemarivom metabolizmu(< 2% doze pronađe se u mokraći u obliku metabolita), da ne inhibira metabolizam lijekova in vitro i ne veže se za proteine u plazmi, nije vjerojatno da će izazivati ili ulaziti u farmakokinetičke interakcije.

In-vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.
Istraživanja in vitro ukazuju da ertapenem ne inhibira transport digoksina i vinblastina posredovan P-glikoproteinom, kao i da ertapenem nije supstrat za transport posredovan P-glikoproteinom.

In vitro studies in human liver microsomes indicate that tigecycline does not inhibit metabolism mediated by any of the following 6 cytochrome P450(CYP) isoforms: 1A2, 2C8, 2C9, 2C19, 2D6, and 3A4 by competitive inhibition.
In vitro ispitivanja s ljudskim jetrenim mikrosomima upućuju na to da tigeciklin ne inhibira metabolizam posredovan bilo kojim od slijedećih 6 izooblika citokroma P450(CYP): 1A2, 2C8, 2C9, 2C19, 2D6 i 3A4 kompetitivnom inhibicijom.

Dasabuvir does not inhibit organic anion transporter(OAT1) in vivo and is not expected to inhibit organic cation transporters(OCT2), organic anion transporters(OAT3), or multidrug and toxin extrusion proteins(MATE1 and MATE2K) at clinically relevant concentrations; therefore, Exviera does not affect medicinal product transport by these proteins.
Dasabuvir ne inhibira prijenosnik organskih aniona( OAT1) in vivo te se ne očekuje da će inhibirati prijenosnike organskih kationa( OCT2), prijenosnik organskih aniona( OAT3) niti proteine za ekstruziju više lijekova i toksina( MATE1 i MATE2K) pri klinički značajnim koncentracijama; stoga Exviera ne utječe na prijenos lijekova tim proteinima.

Studies in human liver microsomes and recombinant enzyme systems have shown that maraviroc does not inhibit any of the major P450 enzymes at clinically relevant concentrations CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4.
Ispitivanja na jetrenim mikrosomalnim enzimima čovjeka i rekombinantnim enzimskim sustavima pokazala su da maravirok u klinički relevantnim koncentracijama ne inhibira glavne enzime P450 CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 i CYP3A4.

In vitro studies indicated that axitinib does not inhibit CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, or UGT1A1 at therapeutic plasma concentrations.
Ispitivanja in vitro pokazala su da u terapijskim koncentracijama u plazmi aksitinib ne inhibira CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5 ni UGT1A1.

In vitro studies indicate that raltegravir is not a substrate of cytochrome P450(CYP) enzymes, does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A, does not induce CYP3A4 and does not inhibit P-glycoprotein-mediated transport.
Istraživanja in vitro pokazuju da raltegravir nije supstrat enzima citokroma P450(CYP), ne inhibira CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 ili CYP3A, ne inducira CYP3A4 niti inhibira transport posredovan P-glikoproteinom.

In vitro metabolism studies suggest that methylnaltrexone bromide does not inhibit the activity of CYP1A2, CYP2E1, CYP2B6, CYP2A6, CYP2C9, CYP2C19 or CYP3A4, while it is a weak inhibitor of the metabolism of a model CYP2D6 substrate.
In vitro ispitivanja metabolizma pokazuju da metilnaltreksonbromid ne inhibira aktivnost CYP1A2, CYP2E1, CYP2B6, CYP2A6, CYP2C9, CYP2C19 ili CYP3A4, dok je istovremeno slabi inhibitor metabolizma modela CYP2D6 supstrata.

Since vildagliptin is not a cytochrome P(CYP) 450 enzyme substrate and does not inhibit or induce CYP 450 enzymes, it is not likely to interact with active substances that are substrates, inhibitors or inducers of these enzymes.
S obzirom da vildagliptin nije supstrat enzima citrokroma P(CYP) 450 i ne inhibira niti inducira CYP 450 enzime, nije vjerojatno da će ući u interakciju s djelatnim tvarima koje su supstrati, inhibitori ili induktori tih enzima.

AZU and CA do not inhibit OPRT enzyme activity.
AZU i CA ne inhibiraju enzimsku aktivnost OPRT-a.

Selexipag and its active metabolite do not inhibit transport proteins.
Seleksipag i njegov aktivni metabolit ne inhibiraju transportne proteine.

In human liver microsomes, abacavir did not inhibit cytochrome P450 isoforms.
Abakavir nije inhibirao izoforme citokroma P450 u mikrosomima ljudske jetre.

In human liver cytosol, lenvatinib did not inhibit aldehyde oxidase activity.
U citosolu ljudske jetre lenvatinib nije inhibirao aktivnost aldehid oksidaze.

Please don't inhibit her creativity.
Molimo don l'-t spriječiti njezino stvaralaštvo.

In vitro, topotecan did not inhibit human P450 enzymes CYP1A2, CYP2A6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E, CYP3A or CYP4A nor did it inhibit the human cytosolic enzymes dihydropyrimidine or xanthine oxidase.
In vitro topotekan ne inhibira ljudske P450 enzime CYP1A2, CYP2A6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E, CYP3A ili CYP4A, niti inhibira ljudske citosolne enzime dihidropirimidin ili ksantin oksidazu.